Neovasc (TSX:NVCN, NASDAQ:NVCN) COO Bill Little joined Steve Darling from Proactive to share news the company has announced positive data at the Transcatheter Cardiovascular Therapeutics Conference on use of the Neovasc Reducer in patients who have angina with non-obstructive coronary artery disease. Little telling Proactive the data, from the first 11 patients in a clinical trial in Israel, showed Coronary microvascular flow parameters improved, symptoms of angina improved, and Functional capacity which was a 6 Minute Walk Test also showed improvement.
Neovasc uses conference to announce positive interim clinical data from Neovasc Reducer use
